

14.i Amount of retinal non-perfusion (Median (IQR))†								
Retinal area	All (n=103)*		Ranibizumab (n=40)		Aflibercept (n=33)*		Bevacizumab (n=30)	
	Cells	DAs	Cells	DAs	Cells	DAs	Cells	DAs
Baseline								
Total area	3 (1.5, 5)	29.3 (14.2, 49.1)	2 (1, 5.8)	20.7 (9.5, 54.3)	4 (1.8, 6)	30.2 (17.2, 56.9)	3 (2, 5)	30.2 (20.7, 46.8)
Posterior (M+R1)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0.25)	0 (0, 0.5)	0 (0, 0)	0 (0, 0)
%(n) subjects with posterior >0	16% (16)	16% (16)	18% (7)	18% (7)	24% (8)	24% (8)	3% (1)	3% (1)
Peripheral (R2 to R4)	3 (1.5, 5)	29.3 (14.2, 49.1)	2 (1, 5.8)	20.7 (9.5, 54.3)	3 (1.8, 6)	30.2 (16.8, 56.9)	3 (2, 5)	30.2 (20.7, 46.8)
M	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
R1	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
R2	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 1)	0 (0, 7.78)	0 (0, 0)	0 (0, 0)
R3	1.5 (0, 3)	14.2 (0, 28.4)	1 (0, 2.4)	9.5 (0, 22.5)	2 (0, 3)	18.9 (0, 28.4)	2 (0, 3)	18.9 (0, 28.4)
R4	2 (0.5, 2)	20.7 (5.2, 20.7)	1 (0.5, 2)	10.4 (5.2, 20.7)	2 (0.8, 2)	20.7 (7.8, 20.7)	2 (0.8, 2)	20.7 (7.8, 20.7)
Week 100								
Total area	3.5 (2, 7)	33.6 (20.7, 64.6)	3 (1.5, 7.8)	30.2 (15.5, 65.5)	4.5 (2, 9.8)	42 (20.7, 88.6)	3 (2, 5)	30.2 (20.7, 49.2)
Posterior (M+R1)	0 (0, 0)	0 (0, 0)	0 (0, 0.8)	0 (0, 3.9)	0 (0, 2)	0 (0, 6.8)	0 (0, 0)	0 (0, 0)
%(n) subjects with posterior >0	23% (23)	23% (23)	25% (10)	25% (10)	31% (10)	31% (10)	10% (3)	10% (3)
Peripheral (R2 to R4)	3.5 (2, 6.6)	33.6 (20.7, 60.1)	3 (1.5, 6.9)	30.2 (15.5, 61.2)	4.3 (2, 8.6)	42 (20.7, 77.1)	3 (2, 5)	30.2 (20.7, 49.2)
M	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 1.6)	0 (0, 0)	0 (0, 0)

	0)				0.9)			
R1	0 (0, 0)	0 (0, 0)	0 (0, 0.4)	0 (0, 2)	0 (0, 1)	0 (0, 5.2)	0 (0, 0)	0 (0, 0)
R2	0 (0, 1.1)	0 (0, 8.8)	0 (0, 1.8)	0 (0, 13.6)	0 (0, 2.9)	0 (0, 22.4)	0 (0, 0.5)	0 (0, 3.9)
R3	1.5 (0, 3)	14.2 (0, 28.4)	1.3 (0, 3)	11.8 (0, 28.4)	2 (0.1, 4)	18.9 (1.2, 37.9)	1.5 (0, 2.5)	14.2 (0, 23.7)
R4	2 (1, 2)	20.7 (10.4, 20.7)	1.8 (1, 2)	18.1 (10.4, 20.7)	2 (1.6, 2)	20.7 (16.8, 20.7)	2 (1, 2)	20.7 (10.4, 20.7)
	Cells	DAs	Cells	DAs	Cells	DAs	Cells	DAs
Change in total area	0.0 (-0.5, 2.0)	0.0 (-5.1, 19.4)	0.0 (-0.5, 2.0)	0.0 (-5.6, 16.6)	0.75 (-0.13, 2.63)	6.5 (0.0, 22.5)	0.0 (-1.38, 1.50)	0.0 (-13.2, 15.2)
Change in posterior	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.38)	0.0 (0.0, 2.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
%(n) subjects with an increase in posterior	17% (17)	18% (18)	18% (7)	18% (7)	25% (8)	28% (9)	7% (2)	7% (2)
Change in peripheral	0.0 (-0.5, 2.0)	0.0 (-5.1, 18.4)	0.0 (-0.6, 1.6)	0.0 (-5.7, 16.6)	0.5 (0.0, 2.1)	5.4 (0.0, 20.8)	0.0 (-1.4, 1.5)	0.0 (-13.2, 15.2)

†Medians(IQR) except written otherwise

*Data were missing for one aflibercept patient at 100 weeks.

14.ii	Difference in medians (95% CI)*		Difference in medians (95% CI)*	
	Aflibercept - Ranibizumab		Bevacizumab - Ranibizumab	
	Cells	DA	Cells	DA0.0
Change in total area	0.8 (-0.5, 1.8)	6.5 (-1.1, 10.8)	0.0 (-1.0, 0.5)	0.0 (-8.6, 4.6)
%(N) patients with an increase in posterior	7.5% (-11.6%, 27.0%)	10.6% (-8.9%, 30.6%)	-10.8% (-25.6%, 3.9%)	-10.8% (-25.6%, 3.9%)
Change in peripheral	0.5 (-0.3, 1.5)	5.4 (-2.4, 13.8)	0.0 (-1.0, 0.5)	0.0 (-9.5, 4.7)

*95% confidence intervals for the changes were obtained using the nonparametric bootstrap percentile method with 100,000 samples.